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Abstract
Introduction: Rheumatoid arthritis (RA) is considered a T cell driven autoimmune disease, therefore, the ability of B
cell depleting biologics, e.g., anti-CD20 antibodies, to alleviate RA is unclear. This study examined the proportions
of IL-17-secreting lymphocytes in the blood of healthy subjects and RA patients and determined if Th17 cells
belong to a CD20+ subset of T cells.
Methods: Fluorescence-activated cell sorting and confocal microscopy verified CD3, CD4/CD8 and CD20-staining
of T cells. IL-17 secretion was determined using a commercial assay.
Results: In healthy subjects and RA patients blood, the median percentage of total CD20+ lymphocytes was
similar (7.5%; n = 6 and 10.3%; n = 9, respectively) and comprised predominantly of B cells (~ 86%). However, 2-4%
of CD3+ T cells from both healthy subjects (n = 7) and RA (n = 8) individuals co-expressed CD20. The peripheral
blood of healthy subjects contained few IL-17-secreting CD20+ T cells (< 0.1%; n = 6). In contrast, in RA blood a
median and interquartile range % of, 24.2%; IQR 28.5 of IL-17-secreting T cells were CD20+ (n = 9; p = 0.02).
Conclusions: In the blood of RA patients, a greater proportion of Th17 cells are of a CD20+ phenotype compared
to healthy individuals. These cells may represent an additional target for anti-CD20 therapies.
Introduction
Autoimmune diseases such as rheumatoid arthritis (RA)
are characterized by chronic inflammation mediated by
T and B lymphocytes that accumulate at sites of inflam-
mation (for example, in the synovial joints of patients
with RA). Within these sites, a number of subclasses of
autoreactive T cells with specific functions (for example,
Th1, Th2, or Th17) may play a role in the pathology of
the disease and stimulate B-cell proliferation and auto-
antibody production [1]. In particular, Th17 cells have
recently been implicated in the pathogenesis of RA [2].
A cell surface membrane protein, CD20, is found pre-
dominantly on B cells, where it functions to aid prolifera-
tion and cell cycle progression. Surface CD20 is the
target for the biological therapeutic, rituximab (RTX), a
chimeric monoclonal antibody [3]. Anti-CD20 therapies
have been successful in destroying malignant B lympho-
cytes expressing this surface marker [4]. More recently,
trials to remove circulating B cells from patients with
autoimmune disorders such as systemic lupus erythema-
tosus (SLE) and RA have revealed significant clinical
activity of anti-CD20 monoclonal antibodies via mechan-
isms that are not yet completely understood [5-7].
Of note, the anti-CD20-induced depletion of B cells by
biologics such as RTX may not be the only mechanism
of action accounting for therapeutic efficacy. Indeed,
although CD20 is thought of as located primarily on the
membrane of B lymphocytes, some studies indicate that
a proportion of T lymphocytes also express CD20 [8,9].
This is particularly interesting in view of recent evidence
that suggests that specific subsets of T lymphocytes (for
example, Th17 cells) may drive the pathological process
that is evident in complex autoimmune disorders such
as RA. However, the extent and nature of this CD20+
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T-cell subset in health and disease-and therefore the
possible relevance of this subset in RA-are not yet
known. In addition, some groups have suggested that
these cells may be T-cell/B-cell doublets [10].
In this study, we confirm that CD20+ T cells are pre-
sent in the peripheral blood of patients with RA,
although the percentage of these cells is small and the
proportion of CD20+ T cells in peripheral blood of
patients with RA is similar to that of healthy subjects.
Importantly, however, we now show that the median
percentage of IL-17-secreting cells that are CD20+ T
cells is increased by 240-fold in RA patients compared
with healthy subjects. Th17 cells are known to play a
crucial role in a number of autoimmune diseases,
including RA [11]. This finding highlights the possibility
that the mode of action of CD20-targeted therapy might
include the targeted depletion of CD20+ Th17 cells. We
propose that CD20+ Th17 cells may be potential targets
for selective depletion in RA.
Materials and methods
Patients, healthy subjects, and cell isolation
All diagnoses were made according to the American
College of Rheumatology criteria for RA [12]. Nine of
the patients were positive for rheumatoid factor or anti-
citrullinated peptide antibodies or both. The patients
had a mean age of 60.4 years (range of 37 to 100 years),
a mean (± standard deviation) disease duration of 19.9 ±
6.8 years, a tender joint count of 2.5 ± 3.3, a swollen
joint count of 3.2 ± 3.6, a health assessment question-
naire (HAQ) score of 35.1 ± 17.8, and a disease activity
score using 28 joint counts-C-reactive protein (DAS28-
CRP) of 3.9 ± 1.3. None of the patients recruited was on
anti-tumor necrosis factor or other biological therapeu-
tics. All patients were being treated with methotrexate.
Lymphocytes were isolated from the peripheral blood
and synovial fluid (SF) of patients with RA and from the
peripheral blood of healthy subjects by using Ficoll-
Paque Plus (GE Healthcare, Little Chalfont, Buckin-
ghamshire, UK and employing a density gradient centri-
fugation method in accordance with the instructions of
the manufacturer. Flow cytometry analysis was carried
out on either total peripheral blood mononuclear cells
(PBMCs) or isolated peripheral blood lymphocytes.
Cytokine analysis was performed on collected plasma
and SFs collected from RA subjects and plasma from
healthy subjects. The ethics review board of the Multi-
Regional Ethics Committee approved the study (MREC
06/Q2102/56), and all blood samples were obtained with
signed consent from the patients and healthy subjects.
Phenotype analysis of CD20+ and CD20- T cells
After isolating the lymphocytes or PBMCs from both
healthy subjects and RA subjects, each subpopulation of
lymphocytes was delineated by staining for CD3 (T
cells) or CD19 (B cells) by employing phycoerythrin
(PE)-conjugated anti-CD3 or PE-conjugated anti-CD19
monoclonal antibodies (BioLegend, San Diego, CA,
USA). Then, the number of CD20+ cells in each sample
group was determined by co-staining with fluorescein
isothiocyanate (FITC)-conjugated anti-CD20 (BioLe-
gend). Appropriately conjugated IgG antibodies-mouse
anti-human FITC-IgG2b, K isotype, mouse FITC-IgG1,
and PE-mouse anti-human IgG1 (BioLegend)-were used
as isotype controls. In a number of healthy subject sam-
ples, cells were triple-stained with anti-CD3-FITC, anti-
CD20-PE, and anti-CD19-allophycocyanin (APC) or
with anti-CD3-CyQ (Cyquant), anti-CD20-FITC, and
anti-CD19-PE. Alternatively, cells were stained for CD4-
FITC or CD8-FITC, CD19-APC, and CD20-FITC on
occasion. To confirm that the anti-CD20-conjugated
antibodies were binding specifically to surface-expressed
CD20 antigen, isolated PMBCs were washed and pre-
incubated with 5 μg/mL RTX (Hoffman-La Roche,
Basel, Switzerland) on ice for 15 minutes and washed
again before beginning the staining procedures for flow
cytometry analysis (Accuri flow cytometer; BD Bios-
ciences, San Jose, CA, USA).
Cell stimulation and IL-17 generation and detection in
CD20+ T cells
IL-17 production in individual cells can be measured in
a number of ways, including intracellular cytokine stain-
ing (ICS), ELISPOT (enzyme-linked immunosorbent
spot), or cytokine capture assays. In the present study,
both intracellular and secreted IL-17 IL-17 was assessed.
The advantage of the IL-17 capture assay over ICS is
that the former monitors only ‘live actively secreting
cells’. In contrast, intracellular staining techniques allow
the monitoring of previously produced IL-17 in fixed
cells. The number of IL-17-secreting T cells that were
also CD20+ was identified by using an IL-17 cell detec-
tion kit (Miltenyi Biotec, Bergisch Gladbach, Germany)
and co-staining with anti-CD20-FITC (BioLegend).
Briefly, 1.5 × 106 peripheral blood PBMCs per well were
suspended in 150 μL of RPMI and 5% vol/vol autolo-
gous serum and 1% glutamine/penicillin/streptomycin
and incubated overnight at 37°C, 5% CO2/21% O2.
Then, cells were stimulated with the superantigen
CytoStim (20 μL/mL medium; Miltenyi Biotec) for 4
hours at 37°C. Next, the cells were washed several times
in RPMI. Cells from unstimulated wells were also col-
lected to serve as negative controls. An IL-17 catch
reagent consisting of an anti-IL-17A monoclonal anti-
body (mouse IgG1) conjugated to CD45-specific mono-
clonal antibody (mouse IgG2a) was added to label IL-
17-secreting cells, followed by 5-minute incubation on
ice and 45-minute incubation under slow rotation at 37°
Eggleton et al. Arthritis Research & Therapy 2011, 13:R208
http://arthritis-research.com/content/13/6/R208
Page 2 of 14
C to allow for optimal IL-17 secretion to occur. Cells
were subsequently washed and incubated with a 10-μL
aliquot of IL-17 detection antibody on ice for 10 min-
utes. Additional staining antibodies (for example, CD19-
FITC and CD4-APC) were added at this stage and ana-
lyzed immediately by flow cytometry (Quanta SC flow
cytometer; Beckman Coulter, High Wycombe, UK) in
accordance with the instructions of the manufacturer.
To exclude the possibility of detecting false-positive T
cells expressing CD20, by analyzing T-cell/B-cell doub-
lets, stringent gating was performed by using pulse
height-versus-width parameter settings. Cells were co-
stained with CD19-FITC to ensure that no contaminat-
ing B cells were present as either T-cell/B-cell doublets
or B cells alone, as assessed with a Quanta SC flow cyt-
ometer and Cell Lab Quanta™ software (Beckman
Coulter). This particular flow cytometer analyzes cells
on the basis of accurate volume/diameter measurements
(not forward side scatter, which is an arbitrary measure-
ment of cell size) and side scatter analysis. Therefore, it
is possible to gate cells of a specific cell diameter, elimi-
nating the possibility of analyzing T-cell-B-cell
aggregates.
For the analysis of surface phenotype and intracellular
staining of IL-17, PBMCs were plated into 24-well cul-
ture plates (Nunc, Naperville, IL, USA) at 1 × 107/mL in
RPMI as described above and cultured overnight at 37°
C, 5% CO2/21% O2. The following morning, aliquots of
107 cells/mL were stimulated alone with 20 μL of
CytoStim for 6 hours at 37°C, with the protein transport
inhibitor Brefeldin A being added at a final concentra-
tion of 5 μg/mL after 2 hours of this incubation period.,
For phenotype analysis and intracellular staining of IL-
17, aliquots of CytoStim-treated and untreated cells (106
PBMCs) were transferred to Eppendorf tubes and the
cells were washed in cell staining buffer (BioLegend)
and stained with mouse anti-human antibodies against
CD20-PE, CD19-PE, or IgG1-PE isotype control and
then fixed and permeabilized with fixation buffer (Bio-
Legend) and permeabilization buffer (BioLegend),
respectively, before being probed for IL-17 with rabbit
anti-human IL-17-FITC or IgG1-FITC isotype control
antibodies. The cells were spun onto slides and treated
with SlowFade Gold antifade reagent with 4’,6-diami-
dino-2-phenylindole (DAPI) (Invitrogen, Paisley, UK).
Multiple slides were examined on a Olympus BX60
fluorescent microscope (Olympus, Tokyo, Japan)
mounted with a Nikon S10 digital camera (Nikon Cor-
poration, Tokyo, Japan), and images of each experimen-
tal condition were acquired.
Immunoassay of cytokines
Plasma was separated from EDTA (ethylenediaminete-
traacetic acid) anti-coagulated peripheral blood and
stored at -80°C for later cytokine assays. Plasma and SF
cytokine concentrations were analyzed by using com-
mercially available IL-17, IL-21, and IL-23 enzyme-
linked immunosorbant assay (ELISA) Quantikine kits
(R&D Systems, Inc., Minneapolis, MN, USA). Measure-
ments were performed in duplicate in accordance with
the instructions of the manufacturer.
Confocal microscopy
PBMCs of healthy subjects were stained with anti-CD3-
Pacific blue, anti-CD19-APC, and anti-CD20-PE. Subse-
quently, CD3+/CD19-/CD20- and CD3+/CD19-/CD20+
cells were sorted by using a MoFlo high-speed cell sor-
ter (Cytomation, Fort Collins, CO, USA). Sorting was
performed at a high purity setting, which restricted the
isolation to single cells and excluded doublets. Subse-
quently, the two cell populations were additionally
stained with a combination of anti-CD4-FITC and anti-
CD8-FITC. Afterward, staining was analyzed by confocal
microscopy (HCX PL APO × 63/1.3 glycerin objective;
Leica DM IRE2 Inverted microscope; Leica, Wetzlar,
Germany) by using InVivo software (Media Cybernetics,
Inc., Bethesda, MD, USA) and a Stanford Photonics XR/
Mega-10I (intensified) charge-coupled device (CCD)
camera (Stanford Photonics, Inc., Palo Alto, CA, USA).
Statistical analysis
Data were analyzed by using the Mann-Whitney U test.
Probability values of P less than 0.05 were considered to
be statistically significant.
Results
CD20+/CD3+ lymphocytes are T cells and not T-cell/B-cell
doublets
The possible presence of CD20+ T cells was initially
analyzed by performing triple-color flow cytometry for
CD3, CD19, and CD20 on PBMCs from healthy volun-
teers. Briefly, fluorescence analyses were confined to
lymphocytes by gating on the lymphocyte population
within the forward scatter/sideward scatter dot plot
(Figure 1A, gate P1). Within this lymphocyte popula-
tion, the CD19+/CD20+ double-positive B cells were
excluded from subsequent analysis (Figure 1A, ii). The
remaining lymphocytes were evaluated for CD3 and
CD20 expression, which revealed that a small propor-
tion of CD3+ T cells was also dimly positive for CD20
(Figure 1A, iii). The specificity of this staining was ver-
ified by performing an isotype control staining, which
revealed no non-specific fluorescence (Figure 1B). To
further confirm that the CD20 signal detected for the
CD3/CD20 double-positive T cells was CD20-specific,
PBMCs were pre-incubated with excess anti-CD20
antibody RTX. Subsequent immunofluorescent staining
identified that RTX completely abrogated the CD20
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staining of CD3/CD20 double-positive staining. In
addition, the intensity of the CD20 signal on B cells
was diminished by 2-3 log fluorescence intensity (Fig-
ure 1C, ii). We performed additional triple-staining for
CD3, CD19, and CD20 on peripheral blood lympho-
cytes of healthy subjects by using flow cytometry (Fig-
ure 2A) with and without CD4 and CD8 staining to
delineate the subpopulations of T cells showing
Figure 1 Gating and control rationale for CD20+ T-cell selection. (A) (i) Typical flow cytometry dot plot of the forward and side scatter of
peripheral blood mononuclear cells (PBMCs). (ii) Dot plot of P1 gated cells (as indicated in A) stained with CD20-FITC and CD19-PE and shown
in ‘R2’. (iii) Dot plot of P1 gated cells, except ‘R2’, stained with CD20-FITC and CD3-CyQ. (B) (i) Typical flow cytometry dot plot of the forward
and side scatter of PBMCs. (ii) Dot plot of P1 gated cells stained with isotype control IgG-FITC and isotype control IgG-PE and shown in ‘R2’ (iii).
Dot plot of P1 gated cells, except ‘R2’, stained with isotype control IgG-FITC and isotype control CD3-CyQ. (C) (i) Typical flow cytometry dot plot
of the forward and side scatter of PBMCs. (ii) Dot plot of P1 gated cells stained with CD20-FITC and CD19-PE post-RTX treatment and shown in
‘R2’. (iii) Dot plot of P1 gated cells, except ‘R2’, stained with CD20-FITC and CD3-CyQ post-RTX incubation.
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Figure 2 Detection of subsets of CD3+CD20+ T cells in healthy subjects. (A) (i) Typical flow cytometry dot plots of the forward side scatter
(FSC) against sideward scatter (SSC) of peripheral blood lymphocytes (PBLs). Within the lymphocyte population, CD3-FITC/CD19-APC/CD20-PE
triple-staining was performed on the cells. This staining enabled visualization of (ii) double-positive CD3+CD20+, (iii) CD3+CD19-, and (iv) CD19
+CD20+ events. (B) PBLs expressing a CD3+ phenotype (a-CD3-FITC) were gated and evaluated for their expression patterns of CD19 (a-CD19-
APC) and CD20 (a-CD20-PE). Alternatively, PBLs were stained with a-CD4-FITC or aCD8-FITC and a-CD19-APC/a-CD20-PE to determine the
percentage of CD4+/CD20+/CD19- and CD8+/CD20+/CD19- cells. (C) Lymphocytes were stained with a-CD3-Pacific blue/a-CD19-APC/a-CD20-
FITC, whereupon a-CD3+/a-CD19-/a-CD20+ and a-CD3+/a-CD19-/a-CD20- cells were sorted as illustrated with the sort plots. Subsequently,
sorted populations were stained with a mix of a-CD4-PE/a-CD8-PE and the respective populations were analyzed by confocal microscopy for
CD4/CD8 (red pseudo color) and CD20 (green pseudo color). Confocal microscopy was performed with a Leica DM IRE2 Inverted microscope
(objectives: HCX PL APO 63 ×/1.3 with glycerin; camera: Stanford Photonics XR/Mega-10I (intensified) charge-coupled device (CCD) camera;
software: Yokogawa Confocal Scanner Unit CSU10). This experiment was performed on four occasions with similar results. APC, allophycocyanin;
FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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positivity for CD20 (Figure 2B). In the illustrated flow
cytometry plots of a representative sample, approxi-
mately 1.5% of CD3+ cells were also CD20+, whereas
CD3+ cells did not express the B-cell marker CD19
(Figure 2A). In line with earlier findings [9], the stain-
ing intensity for CD20 on these T cells was an order
of magnitude lower than that on CD20/CD19 double-
positive B cells. Within the CD3+ population of four
healthy subjects analyzed, the median percentage
(interquartile range, or IQR) of cells, which were CD3
+/CD20+, was 1.20% (IQR 1.02), and the ratio of CD8
to CD4 cells was 3:1 (Figure 2B). We performed flow
cytometric cell sorting on four healthy subjects to
obtain the CD3+/CD20+/C19- cell population. Subse-
quent confocal microscopy of these CD3+/CD20
+/CD19- cells (Figure 2C) demonstrated that they also
express the T-cell marker CD4 or CD8. Importantly,
CD3+/CD20+/CD19- cells were clearly identifiable as
single cells and not, as previously suggested, as T-cell/
B-cell doublets [10]. Interestingly, the expression of
CD20 on the T cells appears rather patchy and may
reflect cross-linking of anti-CD20 to CD20, which has
been observed to result in CD20 translocating to lipid
rafts [13]. Taken together, these results confirm the
presence of CD20+/CD3+ T cells in peripheral blood of
healthy volunteers.
The frequency of CD20+ T lymphocytes is not elevated in
the blood of RA patients compared with healthy subjects
Initially, we assessed the percentage of CD20+ lympho-
cytes (B and T cells combined) in the peripheral blood
of healthy subjects and RA patients. We observed a
similar median percentage of total peripheral blood
lymphocytes (approximately 8% to 10%) that were
CD20+ (Figure 3A). Next, we determined the relative
frequency of CD20/CD3 double-positive T cells in the
blood of RA patients and healthy subjects by flow
cytometry. The median percentages with IQR, of this
cell subset were similar in the peripheral blood of
healthy subjects and RA patients (Figure 3B): 2.5%
(IQR 3.1) and 3.7% (IQR 2.8), respectively (Figure 3B).
In two of these patients, the percentages of CD20/CD3
double-positive T cells were 8.5% and 1.3%, respec-
tively, in their SF and 3.28% and 0.37%, respectively, in
their peripheral blood. In addition, the median percen-
tages of CD19/CD20 double-positive B cells present in
peripheral blood lymphocytes of healthy and RA sub-
jects were identified by flow cytometry (Figure 3C) and
consisted of 84.8% (IQR 10.2) and 87.0% (IQR 9.7)
CD19+/CD20+ B cells in healthy subjects and RA
patients, respectively. Similarly, in the SF available
from two patients with RA, the percentages of CD19/
CD20 double-positive B cells were 60.0% and 79.0% in
the two SF samples.
The median percentage of IL-17-secreting CD20+ T
lymphocytes is significantly elevated in rheumatoid
arthritis compared with healthy control subjects
Since recent studies highlight a possibly central role for
IL-17-secreting T lymphocytes in the pathogenesis of
RA, we next assessed whether the percentages of IL-17-
secreting lymphocytes in the peripheral blood of healthy
subjects and RA patients differed. We excluded analysis
of doublets in flow cytometry data by gating on CD20+
lymphocytes between 5.0 and 8.5 μm in diameter (Fig-
ure 4A). Gated cells were then analyzed for double-
staining with CD20 and IL-17 (Figure 4B). IL-17-produ-
cing CD19-/CD20+ gated lymphocytes were detected in
PBMC preparations following 4 hours of CytoStim sti-
mulation. Typical dot plots of IL-17-secreting lympho-
cytes from a healthy subject (Figure 4B, left panel)
compared with a patient with RA (Figure 4B, right
panel) are shown.
Others have reported that between 0.04% and 2% of
CD4 T cells secrete IL-17 following CytoStim stimula-
tion [14]. In our study, IL-17 was produced by 0.0% to
0.29% of healthy subject PBLs (n = 6) and 0.03% to 1.2%
of RA patient PBLs (n = 9). The median percentages
(with IQRs) were 0.02% (0.2) and 0.5% (0.8), in HS and
RA respectively. Since about 70% of PBLs in HS and RA
blood are T cells, the values in our study are in approxi-
mate agreement with another study that looked at T
cells directly [14]. As shown in Figure 4C (left panel),
there was a 45-fold increase (P = 0.01) in the median
percentage of IL-17-secreting T cells in the blood of RA
patients compared with healthy control subjects. We
further looked at the ratio of CD8 to CD4 cells expres-
sing CD20 and secreting IL-17 in a separate cohort of
healthy subjects. Among the CD20+ IL-17-secreting T
cells, 45% co-expressed CD4 and 55% co-expressed
CD8.
As we observed a higher percentage of IL-17-secreting
T cells in the peripheral blood of RA patients compared
with healthy control subjects, we were interested to
know what proportion of these cells were also CD20+ T
cells. We captured the IL-17-secreting lymphocytes and
screened them for CD20 expression by flow cytometry.
As shown in Figure 4C (right panel), in patients with
RA, there was an increase of two orders of magnitude
(P = 0.02) in the median percentage of IL-17-secreting
cells that were also CD20+ (24.2%) compared with
healthy control individuals (< 0.01%). This represented a
240-fold increase in the median percentage of IL-17-
secreting cells that were also CD20+ in RA patients
compared with healthy subjects. We sought to obtain
confirmatory visible evidence of CD20+ cells generating
IL-17 directly: PBMCs were stimulated with CytoStim
and treated with Brefeldin A (to prevent IL-17 secretion)
and triple-stained. Fresh cells were stained with CD20-
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PE or CD19-PE (for phenotype analysis); fixed, permea-
bilized, and stained for intracellular IL-17-FITC. Finally,
the cells were treated with DAPI (for nuclear staining).
As shown in Figure 5, CD20bright cells (middle column,
Figure 5D-F) depicted with arrows, were also IL-17+. As
expected from the flow cytometry analysis above, some
CD20dim cells were positive for IL-17 staining. In con-
trol experiments, CD19+ cells (right-hand column, Fig-
ure 5G-I) were negative for IL-17 intracellular staining.
As summarized in Figure 6A, approximately 2% to 4%
of peripheral blood T cells were CD20+ whereas 80% of
B cells were CD20+. In healthy subjects, only 0.02% of
their peripheral blood T cells secreted IL-17 and less
than 0.01% of these IL-17-secreting cells were actually
CD20+. In contrast, in the patients with RA, 0.45% of
their total peripheral T cells secreted IL-17, of which
24.2% were CD20+. The detection of greater numbers of
Th17 cells in RA patient blood upon stimulation with
CytoStim suggests that CD20+ and CD20- Th17 cells
are already developed and differentiated in higher num-
bers in RA patient blood. Thus, we measured the con-
centrations of IL-17 in the plasma (and SF where
Figure 3 Expression of CD20 on B and T lymphocytes from the peripheral blood of healthy subjects (HS) compared with rheumatoid
arthritis (RA) patients, as obtained by flow cytometry. (A) The percentage of CD20+ peripheral blood lymphocytes in HS and RA patients.
(B) The percentage CD3+CD20+ T cells in HS and RA patients. (C) The percentage of CD19+CD20+ B cells in HS and RA patients as analyzed by
flow cytometry. The bars represent the median percentage and interquartile range. The expression patterns of CD20+ cells represent data from
11 HS and 8 RA blood samples in total.
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Figure 4 CD20+, IL-17-secreting, and IL-17-secreting/CD20+ lymphocytes in healthy subjects (HS) and rheumatoid arthritis (RA)
patients. (A) Dot plot of size versus CD20 positivity in representative peripheral blood lymphocyte (PBL) samples from an HS and an RA patient.
(B) Typical flow cytometry dot plots showing the proportion of CD20+ and IL-17-secreting lymphocytes in representative PBL samples from an
HS (left panel) and an RA patient (right panel). Each dot plot shows the proportion of CD20+ cells (lower right quadrant), IL-17-secreting cells
(upper left quadrant), and IL-17-secreting CD20+ cells (upper right quadrant). (C) The proportion of PBLs that were IL-17-secreting in HS (n = 6)
and RA subjects (n = 9, left panel) and the proportion of IL-17-secreting cells that were specifically CD20+ T cells (right panel). The horizontal
bars represent the median percentage and interquartile range of each group. IL, interleukin.
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available). We also measured IL-21 and IL-23 concen-
trations, as both of these cytokines have been implicated
in Th17 cell development [15,16]. We did not detect IL-
17 in the plasma of our healthy subjects or in the meth-
otrexate-treated RA subjects (Figure 6B) but did detect
IL-17 in the SF of three out of six patients (4.40 ± 28.8
pg/mL, range of 0.41 to 28.7 pg/mL; n = 3). Since IL-21
and IL-23 may enhance the development of Th17 cells,
these cytokines were measured in the plasma of healthy
subjects and the plasma and SF of patients with RA. IL-
21 levels were significantly higher in the plasma of RA
patients compared with control plasma (129.3 ± 162.7
pg/mL and 33.9 ± 10.2 pg/mL, respectively; P = 0.01).
IL-21 was also detectable in the SF of five of the RA
patients screened above (39.6 ± 41.6 pg/mL), but this
was significantly lower (P < 0.05) compared with the
plasma IL-21 levels in the matched RA plasma samples.
IL-23 was detectable in all plasma samples of healthy
Figure 5 Immunohistochemical detection of CD20+ lymphocytes with intracellular staining for IL-17. (A) Peripheral blood mononuclear
cells were isolated from peripheral blood and stimulated with CytoStim followed by Brefeldin A and stained histochemically with Diff-Quick™.
(B-I) Cells were then phenotyped for IgG1-PE isotype control (C), CD20-PE (E), or CD19-PE (H). The cells were then fixed and permeabilized and
stained for IL-17-FITC, as seen in (C), (F), and (I), respectively. The cells were mounted on slides with antifade fluid supplemented with DAPI for
nuclear staining (B, D, and G). Arrows in the middle column of panels depict triple-stained CD20+ (red) lymphocytes, which are IL-17+ (green).
The right-hand column of panels depicts CD19+ lymphocytes (red), which are IL-17-. Images were viewed at ×1,000 with an Olympus BX60
microscope with C-mount and a Nikon S10 digital camera. The size bar represents 10 μm unless otherwise stated. All specimens were processed
at the same time, as described in Materials and methods. At least 10 fields of view were examined for each panel. DAPI, 4’,6-diamidino-2-
phenylindole; FITC, fluorescein isothiocyanate; IL, interleukin; PE, phycoerythrin.
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Figure 6 Frequency of Th17 cells, and plasma IL-17, IL-21, and IL-23 concentrations. (A) Schematic summarizing the proportions of CD20+
and Th17/CD20+ cell subsets in healthy subjects (HS) and rheumatoid arthritis (RA) patients. (B) Plasma and synovial fluid (SF) concentrations of
IL-17, IL-21, and IL-23 as measured by enzyme-linked immunosorbent assay in RA subjects. The same cytokine concentrations were evaluated in
the plasma of HS for comparison. IL, interleukin; Th, T helper cell.
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control and RA subjects (5.7 ± 12.3 pg/mL and 14.7 ±
21.8 pg/mL, respectively) and detected at low concentra-
tions in only two out of six matched SF samples (Figure
6B).
Discussion
Several anti-CD20 monoclonal antibody therapies are
currently approved or in phase II/III trials to treat auto-
immune disease [17]. These (RTX: Rituxan/MabThera,
ocrelizumab: 2H7; and ofatumumab: Arzerra) are
designed to bind to CD20 on the surface of B cells,
resulting in their elimination. The exact cellular and
molecular mechanism by which the binding of anti-
CD20 monoclonal antibodies to B cells induces cell
death is not fully understood [18]. This is reflected in
the fact that a significant number of patients do not
respond to B-cell depletion therapy [19-21]. The general
assumption is that incomplete/non-responders are not
effectively B cell-depleted, and a number of strategies to
improve the elimination of CD20+ B cells in resistant
RA have been considered [22]. However, the observation
that there are populations of CD20+ T cells may lead to
alternative explanations for the mechanism of action
and incomplete response [9]. For example, it may
explain, in part, why anti-CD20 biologics may provide
beneficial effects in T cell-dominated autoimmune dis-
eases such as multiple sclerosis [23]. Anti-CD20 therapy
is designed to eliminate CD20+ B cells from the periph-
eral blood circulation but has also been shown to elimi-
nate CD20+ T cells in patients with RA [9]. However,
the clinical significance of this has not been studied in
detail. An explanation for the small proportion of CD20
+ T cells in some patients with RA may be that exposure
of CD20+ T cells to RTX masks the CD20 surface anti-
gen. Indeed, in Figure 1C, we demonstrated that pre-
incubation of lymphocytes with RTX masks the CD20
antigen, which is no longer detectable by anti-CD20-
FITC.
In our study, we confirmed the existence of CD20+ T
cells in the peripheral blood of healthy subjects and RA
patients, an observation that was made in the early
1990s [24] and recently reported by Wilk and colleagues
[9] in RA patients at the protein and mRNA levels. A
novel finding in our study is that a significant propor-
tion of CD20+ T cells are also capable of secreting IL-
17, particularly in the RA subjects studied. There is
some variability in the reported values for the percen-
tage of Th17 cells normally residing in human periph-
eral blood. Such variation may be a function of the
assay method used and the IL-17 stimulant employed
[14,25,26]. In our study, medians of 0.02% (range of
0.0% to 0.3%) and 0.45% (range of 0.0% to 1.2%) of
PBLs isolated from healthy controls and RA subjects,
respectively, secreted IL-17 after stimulation with
CytoStim. In a previous study using the same assay and
stimulant, IL-17 was produced by between 0.04% and
2% of T cells (n = 21) [14]. Other researchers have
employed intracellular staining for IL-17 detection and
observed different proportions of lymphocytes positive
for IL-17 secretion. In a study by Shen and colleagues
[26], Peripheral blood mononuclear cells from healthy
control subjects and RA patients were stimulated with a
combination of phorbol myristate acetate and ionomycin
and this led to the detection of approximately 0.5% and
approximately 1% IL-17+ T cells, respectively, whereas
another study demonstrated the presence of 1% of IL-
17-secreting T cells in healthy blood [25]. Other studies
have demonstrated 6% IL-17+/CD161+ T cells [27].
These latter studies employed different stimuli and para-
metric analysis (mean ± standard deviation) and there-
fore are difficult to compare with our results, which
were non-parametric in nature. The above variation
indicates that, dependently of the assay used, there is a
variation in the median or mean percentage of Th17
cells detectable in healthy control blood. Nevertheless,
differences in the percentage of Th17 cells between
healthy control blood and disease blood are a consistent
finding independently of the assay used. In our study,
we used a flow cytometric secretory assay to quantify
actively secreting IL-17 subgroups of cells. To ensure
that CD20+ cells were not simply binding to IL-17
released extracellularly, we performed immunohisto-
chemistry on permeabilized CD20+ cells and confirmed
that a proportion of these cells contained intracellular
IL-17.
Since some autoimmune diseases targeted by T cells
are predominantly CD4-mediated (for example, SLE
[28]) or CD8-mediated (for example, multiple sclerosis
[29]) or both CD4- and CD8-mediated (for example, RA
[30]), we examined the ratio of CD20+ CD4+ and CD8+
cells in a small sample of healthy control subjects (n =
4). Among the T-cell population, we found a greater
number of CD8 cells expressing CD20. This observation
contrasts with the study by Wilk and colleagues [9],
who showed that similar numbers of CD4 and CD8
cells expressed CD20. This may be accounted for by
donor variability. We further examined the CD4/CD8
phenotype of CytoStim-stimulated IL-17-secreting,
CD20+ T cells from a separate group of healthy subjects
(n = 11). We found CD20+IL-17+ T cells positive for
CD8 or CD4 in equal numbers. However, given that
there are approximately twice as many CD4 cells as
CD8 cells in the peripheral blood T cell population, this
would suggest that CD8 T cells do preferentially express
IL-17.
A criticism of the previous study by Wilk and collea-
gues [9] was that CD3+CD20+ cells may be an artefact
of T-cell selection and may actually represent T-cell/B-
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cell doublets [10]. Wilk and colleagues [31] vigorously
rejected this possibility. Another concern was the use of
one type of flow cytometer to detect CD20+ T cells [10].
To address this concern, we used two types of flow cyt-
ometers, as well as fluorescence activated cell sorting in
combination with confocal microscopy. In our flow
cytometry analyses, cells were gated either according to
forward and side scatter (Accuri flow cytometer; BD
Biosciences, San Jose, CA, USA) or according to side
scatter and electronic cell volume/diameter, allowing
one to distinguish cells as single cells on the basis of
size (Quanta SC flow cytometer). Using these different
instruments, we found, in agreement with Wilk and col-
leagues [9,31], that the CD20+/CD3+ double-positive
cells were singlets, which were dimly positive for CD20.
In addition, single cells, sorted by using a high-speed
cell sorter, were identified by confocal microscopy to be
positive for the cell markers CD4 or CD8 and CD20.
Thus, the CD20+ cells analyzed here are, beyond a
doubt, CD19- T-cell singlets. In addition, Wilk and col-
leagues [9] demonstrated by real-time polymerase chain
reaction that CD3+ T cells were expressing low levels of
CD20, but not CD19 at the mRNA level. In our study,
the intensity of CD20 protein expression on the surface
of CD3 cells was an order of magnitude lower compared
with CD20 expression on B cells, and this would reflect
the lower levels of the mRNA expression observed by
Wilk and colleagues [9]. Moreover, the expression of
CD20 on T cells appeared patchy and this has not been
observed on this subset of lymphocytes. However, CD20
expression on B cells upon cross-linking with anti-CD20
is heterogeneous and is thought to represent a cluster-
ing of CD20 and other molecules such as Fas into
patches [32]. It may be that cross-linking of anti-CD20
to CD20 on T cells leads to a similar heterogeneous
localization of CD20 and other molecules into raft-like
structures on the cell surface, which presents as a pat-
chy expression of CD20.
Prior to the present study, it was unknown whether
the CD20+ T cells isolated from healthy subjects and
RA peripheral blood or RA SF were able to secrete the
pro-inflammatory cytokine IL-17, which is implicated in
the pathology of RA [11]. Recently a greater frequency,
and functionally active number, of Th17 cells have also
been observed in SLE [28]. Th17 cells have been impli-
cated in initiating inflammation in numerous autoim-
mune diseases. However, the mechanism of action of
IL-17 and subsequent pathology will depend, in part, on
the location of the Th17 cells. In the case of RA, Th17
cells have been reported in the peripheral blood but
with less frequency in the joints [33], where Th1 cells
appeared more abundant. In contrast, others have
observed both Th17 and Th1 cells in the joints of RA
patients in abundance [34]. This may be explained, in
part, by the plasticity of Th17 cells, which are known to
develop from Th1 cells in the presence of other pro-
inflammatory cytokines [35].
Key findings of the current study are that Th17 cells
are up to 45-fold more abundant in the peripheral blood
of RA patients compared with healthy control subjects
(Figure 4C, left panel) and that approximately 24% of
these IL-17-secreting cells also have a CD20 phenotype
(Figure 4C, right panel). A pool of potentially autoreac-
tive T cells that is capable of secreting the pro-inflam-
matory cytokine IL-17 and that also expresses CD20 is
found in the peripheral blood of patients with RA. Thus
a relatively small but significantly increased number of
Th17 cells is present in the peripheral blood and SF of
RA patients [16] which can potentially drive both
inflammatory and humoral responses in RA [36].
Furthermore, the development of Th17 cells is regulated
by a number of cytokines [15] that are often abundant
during active RA, providing further reasoning for moni-
toring the development and elimination of these pro-
inflammatory cells. Elevated levels of IL-17 have been
shown to correlate with joint damage [37] and may act
as a biomarker of RA pathology [38]. IL-17, a signature
pro-inflammatory cytokine released from Th17 cells and
implicated in RA pathology [11], is also seen in a num-
ber of other conditions, including inflammatory arthritis
[34] and ankylosing spondylitis [26]. The generation of
Th17 cells and their distribution at sites of disease
pathology are of concern, as IL-17 can promote expres-
sion of other pro-inflammatory cytokines and effectors
(for example, IL-6, IL-32, and inducible nitric oxide
synthase), enhance recruitment of neutrophils and
monocytes to inflammatory sites, and promote joint
degradation [11]. Despite observing a greater proportion
of Th17 cells in RA peripheral blood compared with
healthy subject blood, we were unable to detect endod-
genous IL-17 in the plasma of healthy subjects or RA
patients. This is not surprising as the blood samples
used in this study were taken from methotrexate-treated
patients. However, the CD20+/Th17 cells in the blood
were capable of secreting IL-17 in vitro, and this is in
agreement with others [26]. We were able to detect IL-
17 in three of six RA SF samples examined from the
same patients. This is consistent with the concept that,
following migration to the synovial joint space, Th17
cells may actively secrete IL-17. In this regard, the find-
ing of fourfold higher median concentration of IL-21
observed in the plasma of the RA patients compared
with healthy subject plasma suggests that this cytokine
may be important in promoting the proliferation of
Th17 cells or may reflect the secretion of this autocrine
cytokine by the greater number of Th17 cells that we
observed in RA peripheral blood. A recent study has
shown that IL-21 enhances Th17 cell proliferation [39]
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and our results are consistent with this possibility. The
levels of IL-23 in the plasma of healthy subjects and RA
patients were not significantly different, and IL-23 was
dectable in only two of the six RA SF samples we evalu-
ated. This is consistent with the recent studies of others
who have observed low IL-23 levels in RA SF compared
with plasma [40] or detected IL-23 in only about half of
SF samples analyzed [41], making its role in Th17 devel-
opment less clear [16].
’Blockade therapeutics’ to inhibit IL-17 [42] may prove
beneficial. However, anti-CD20 therapeutics already
appears to relieve many of the symptoms provoked by
IL-17 in T cell-mediated diseases such as RA. Our
results would support the notion that anti-CD20 drugs
such as RTX can also bind to CD20+/Th17 cells and
possibly eliminate them before they release pro-inflam-
matory cytokines in the synovial joints. Recent evidence
suggests that RTX treatment of patients with active RA
leads to a reduction in IL-17 and IL-22 production in
vitro [43]. This would support the possibility that anti-
CD20 therapeutics have an unexpected role in influen-
cing the development of Th17 responses.
Conclusions
The identification of Th17+/CD20+ cells in our study
suggests that this population of cells is a possible target
for anti-CD20 therapy. Our results suggest that the
effect of anti-CD20 therapy on the depletion of CD20+
Th17 cells should be monitored in clinical trials.
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